SAN

81.82

+1.02%↑

MRK1

119.15

-1.2%↓

SHL.DE

44.44

+0.11%↑

ARGX

744.6

+2.7%↑

FRE

47.71

+0.97%↑

SAN

81.82

+1.02%↑

MRK1

119.15

-1.2%↓

SHL.DE

44.44

+0.11%↑

ARGX

744.6

+2.7%↑

FRE

47.71

+0.97%↑

SAN

81.82

+1.02%↑

MRK1

119.15

-1.2%↓

SHL.DE

44.44

+0.11%↑

ARGX

744.6

+2.7%↑

FRE

47.71

+0.97%↑

SAN

81.82

+1.02%↑

MRK1

119.15

-1.2%↓

SHL.DE

44.44

+0.11%↑

ARGX

744.6

+2.7%↑

FRE

47.71

+0.97%↑

SAN

81.82

+1.02%↑

MRK1

119.15

-1.2%↓

SHL.DE

44.44

+0.11%↑

ARGX

744.6

+2.7%↑

FRE

47.71

+0.97%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

60.75 0.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

59.95

Max

61.2

Chiffres clés

By Trading Economics

Revenu

49M

76M

Ventes

51M

210M

P/E

Moyenne du Secteur

26.54

76.798

BPA

1.135

Rendement du dividende

1.5

Marge bénéficiaire

35.965

Employés

2,197

EBITDA

49M

84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+48.64% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.50%

2.37%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-18M

3.2B

Ouverture précédente

60

Clôture précédente

60.75

Sentiment de l'Actualité

By Acuity

50%

50%

159 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 déc. 2025, 23:50 UTC

Actions en Tendance

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 déc. 2025, 23:20 UTC

Résultats

Correction to Micron Logs Sales Jump Article

17 déc. 2025, 23:07 UTC

Résultats

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 déc. 2025, 21:37 UTC

Résultats

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 déc. 2025, 23:53 UTC

Market Talk

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 déc. 2025, 23:43 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 déc. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 déc. 2025, 23:05 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 déc. 2025, 23:04 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 déc. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 déc. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 déc. 2025, 22:56 UTC

Acquisitions, Fusions, Rachats

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 déc. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 déc. 2025, 22:49 UTC

Market Talk

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 déc. 2025, 21:58 UTC

Résultats

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 déc. 2025, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 déc. 2025, 21:46 UTC

Résultats

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 déc. 2025, 21:20 UTC

Résultats

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 déc. 2025, 21:10 UTC

Résultats

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 déc. 2025, 21:05 UTC

Résultats

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 déc. 2025, 21:04 UTC

Résultats

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 déc. 2025, 21:04 UTC

Résultats

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 déc. 2025, 21:03 UTC

Résultats

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 déc. 2025, 21:03 UTC

Résultats

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 déc. 2025, 21:03 UTC

Résultats

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 déc. 2025, 21:02 UTC

Résultats

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 déc. 2025, 21:01 UTC

Résultats

Micron Technology 1Q Rev $13.64B >MU

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

48.64% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  48.64%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

159 / 374Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat